about
Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiencyGolimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE studyThe effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE studySirukumab: A Potential Treatment for Mood Disorders?Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE studyThe effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial.Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators.Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials.Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE).Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab.Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T).Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbersInterferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis
P50
Q28190857-DB08CA70-C73C-4DD9-AF3F-8869E6269852Q30717002-FC92B82D-2CCC-4147-8F8A-91FF98678489Q31140425-5E8350EB-9C6E-42D8-909F-CB8C4515409FQ33409403-DEC6B186-DBE4-492A-94D0-A74834183449Q36020178-56D71A22-75D6-4713-83AF-1C9A785CCA06Q37177587-EB1303AA-9ACC-4505-BAB7-102A80651FB8Q37539712-86DA0819-CD20-4860-99C7-4608AE52A045Q37562443-322C203F-2010-4BBC-B83D-7E077EC2F195Q38371450-E6F3402D-5D04-499C-AD76-8C4C7F217011Q38694025-0AD90EE4-2727-4070-B978-6027DCFFE1DDQ39477446-48EF8EE4-BAC0-4D45-B803-2745C1327717Q39925539-2444C7EA-5F40-4FFA-B3BC-3BEDC037A03BQ42149782-1A198587-BCC0-422C-94D5-C336BB2EB272Q44021488-6536F042-D2D7-42FC-8AA3-CA2E4C444640Q44188882-9C587824-4419-4C96-82EE-D64EDC26734BQ45956997-0BA0A315-1475-4BEA-9E14-B9EA3785B874Q51638071-5C083C88-7CD7-4603-9936-006B143A58C0Q52658631-27AF28FE-5049-4A0A-ACDA-5DB929300A7CQ77363170-7606DCA8-89E4-4A77-85D6-2300F2449C19Q83215305-7975BDFB-5B54-4E0B-896C-ADC829BED4A6
P50
description
researcher, ORCID id # 0000-0002-0718-213X
@en
wetenschapper
@nl
name
Benjamin Hsu
@ast
Benjamin Hsu
@en
Benjamin Hsu
@es
Benjamin Hsu
@nl
type
label
Benjamin Hsu
@ast
Benjamin Hsu
@en
Benjamin Hsu
@es
Benjamin Hsu
@nl
prefLabel
Benjamin Hsu
@ast
Benjamin Hsu
@en
Benjamin Hsu
@es
Benjamin Hsu
@nl
P106
P31
P496
0000-0002-0718-213X